Home Cart Sign in  
Chemical Structure| 831234-13-0 Chemical Structure| 831234-13-0

Structure of AC1903
CAS No.: 831234-13-0

Chemical Structure| 831234-13-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AC1903 is an inhibitor of transient receptor potential canonical channel 5 (TRPC5) with IC50 of 14.7 µM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AC1903

CAS No. :831234-13-0
Formula : C19H17N3O
M.W : 303.36
SMILES Code : N1(CC2=CC=CC=C2)C(NCC3=CC=CO3)=NC4=CC=CC=C41
MDL No. :MFCD06609959
InChI Key :OECUWHDVQIITIS-UHFFFAOYSA-N
Pubchem ID :667146

Safety of AC1903

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-7 cells 1 µM 48 h AC1903 increased ADM accumulation in the nuclei of MCF-7 cells Cells. 2023 May 3;12(9):1304
HEK293 cells 1 µM AC1903 increased ADM nuclear accumulation induced by Gd-DTPA treatment Cells. 2023 May 3;12(9):1304
caAT1R-expressing podocytes 30 μM 36 h AC1903 protects podocytes from cell death Science. 2017 Dec 8;358(6368):1332-1336
MCF-7/ADM cells 1 µM 48 h AC1903 increased ADM accumulation in the nuclei of MCF-7/ADM cells Cells. 2023 May 3;12(9):1304
SK-BR-3 cells 1 µM 48 h AC1903 increased ADM accumulation in the nuclei of SK-BR-3 cells Cells. 2023 May 3;12(9):1304
human penile resistance artery smooth muscle cells 0.1 to 30 µM To evaluate the relaxant effects of AC1903 on human penile resistance arteries, results showed that AC1903 was more effective than the TRPC3 inhibitor in relaxing penile resistance arteries from both NoED and ED patients. Int J Mol Sci. 2025 Feb 8;26(4):1431
human corpus cavernosum smooth muscle cells 0.1 to 30 µM To evaluate the relaxant effects of AC1903 on human corpus cavernosum smooth muscle, results showed that AC1903 was more effective than the TRPC3 inhibitor in relaxing corpus cavernosum tissue from both NoED and ED patients. Int J Mol Sci. 2025 Feb 8;26(4):1431
rat corpus cavernosum smooth muscle cells 0.1 to 30 µM To evaluate the relaxant effects of AC1903 on rat corpus cavernosum smooth muscle, results showed that AC1903 was more effective than TRPC3 and TRPC4 inhibitors in relaxing aged rat corpus cavernosum tissue. Int J Mol Sci. 2025 Feb 8;26(4):1431
JEB01 keratinocytes 150 μM 3 h Suppressed G418-induced PTC readthrough and reduced intracellular G418 levels J Biol Chem. 2022 Feb;298(2):101546
mouse podocytes 4.05 μM 24 h AC1903 significantly reduced the expression level of TRPC5, alleviated Adriamycin-induced podocyte migration and apoptosis, and stabilized the cytoskeleton. Front Med (Lausanne). 2024 Sep 5;11:1381479
Human iPSC-derived podocytes 30 µM 24 h Inhibition of TRPC5 channel activity reduces PAN-induced ROS generation and protects podocytes from injury Front Med (Lausanne). 2021 Sep 21;8:721865

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
AT1R transgenic rats FSGS model Intraperitoneal injection 50 mg/kg Twice daily for 7 days AC1903 suppressed severe proteinuria and prevented podocyte loss Science. 2017 Dec 8;358(6368):1332-1336
BALB/c mice Adriamycin-induced podocytopathy model Injection 50 mg/kg Twice daily for 10 days AC1903 alleviated massive albuminuria and foot process effacement in Adriamycin-treated mice, improving foot process integrity. Front Med (Lausanne). 2024 Sep 5;11:1381479
Sprague-Dawley rats PAN-induced nephrosis model Intraperitoneal injection 50 mg/kg Twice daily for seven days AC1903 protects podocyte cytoskeletal proteins and reduces proteinuria by inhibiting TRPC5 channel activity Front Med (Lausanne). 2021 Sep 21;8:721865

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.30mL

0.66mL

0.33mL

16.48mL

3.30mL

1.65mL

32.96mL

6.59mL

3.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories